OmniAb, Inc.

NasdaqGM OABI

OmniAb, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -108.61 M

OmniAb, Inc. Free Cash Flow is USD -108.61 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -6,415.66% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
  • OmniAb, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -1.67 M, a 88.71% change year over year.
  • OmniAb, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -14.76 M, a -7,002.43% change year over year.
  • OmniAb, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -207.88 K.
Key data
Date Free Cash Flow Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities
Market news
Loading...
NasdaqGM: OABI

OmniAb, Inc.

CEO Mr. Matthew W. Foehr
IPO Date Sept. 30, 2021
Location United States
Headquarters 5980 Horton Street
Employees 106
Sector Health Care
Industries
Description

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

Similar companies

VRNA

Verona Pharma plc

USD 48.44

3.75%

ITOS

iTeos Therapeutics, Inc.

USD 7.66

-1.80%

LEGN

Legend Biotech Corporation

USD 31.64

-2.65%

GLUE

Monte Rosa Therapeutics, Inc.

USD 5.56

-1.77%

ERAS

Erasca, Inc.

USD 1.93

-10.23%

OLMA

Olema Pharmaceuticals, Inc.

USD 5.14

6.20%

EWTX

Edgewise Therapeutics, Inc.

USD 27.52

8.65%

CGEM

Cullinan Oncology, Inc.

USD 10.01

-9.33%

IPSC

Century Therapeutics, Inc.

USD 0.94

-3.60%

PMVP

PMV Pharmaceuticals, Inc.

USD 1.35

-2.88%

IDYA

IDEAYA Biosciences, Inc.

USD 22.74

-1.00%

KROS

Keros Therapeutics, Inc.

USD 12.48

-2.65%

IKNA

Ikena Oncology, Inc.

USD 1.51

-1.95%

StockViz Staff

January 15, 2025

Any question? Send us an email